FDA rejects Vanda’s treatment for digestion condition, company rebukes agency’s actions

The FDA flashed a red light on Van­da Phar­ma­ceu­ti­cals’ ex­per­i­men­tal treat­ment for a gas­troin­testi­nal con­di­tion that dis­rupts the di­ges­tion process.

The agency re­ject­ed tradip­i­tant in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.